Daiichi Sankyo, logo

Daiichi Sankyo,(OTC) DSNKY

Market Cap$33.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+194%
5 Year-29%
1 Year-17%
1 Month-2%
$17.99
-0.88%
-0.16Today
Daiichi Sankyo, last closing stock price
MetricPriceDate
Last closeUSD 17.992026-09-29
Daiichi Sankyo, stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.32%USD 19.002026-09-22
1 month-2.12%USD 18.382026-08-28
3 month+12.58%USD 15.982026-07-01
Year to date-14.14%USD 20.952025-12-31
1 year-17.18%USD 21.722025-09-29
3 year-31.13%USD 26.122023-09-29
5 year-29.13%USD 25.382021-09-30
Since inception+194.35%USD 6.172011-11-14

Daiichi Sankyo, Financials at a Glance

Market Cap

$33.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.26T

Net Income (TTM)

¥247.05B

EPS (TTM)

$0.92

P/E Ratio

19.68

Dividend

$0.49

Beta (Volatility)

0.58 (Low)

Price

$17.99

Volume

76,712

Open

$18.38

Previous Close

$17.99

Daily Range

$17.91 - $18.38

52-Week Range

$14.98 - $27.50

Estimated Earnings Date

Oct 30, 2026

DSNKY News

Female scientist with pipette in lab

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Keith SpeightsJun 12, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Daiichi Sankyo,

Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that specializes in the entire lifecycle of drug development, from research and development to manufacturing and distribution. The company offers a diverse portfolio of medicinal products across various therapeutic areas, including oncology, cardiovascular health, and neurology.

Products and Services
  • Oncology treatments like trastuzumab deruxtecan and gefitinib
  • Cardiovascular medications including teneligliptin and edoxaban
  • Neurology products such as mirogabalin and memantine
Growth Outlook
  • Recent quarterly revenue reached JPY 582.3 billion, showcasing strong demand
  • Net income for Q1 was JPY 69.5 billion, reflecting robust profitability
  • Strategic collaborations, like with Guardant Health, enhance product offerings
Financial Highlights
  • Trailing twelve month revenue of JPY 2.3 trillion, indicating steady growth
  • Net profit margin stands at 10.93%, demonstrating effective cost management
  • Dividend yield of 2.64% offers attractive returns to shareholders
Daiichi Sankyo Company, Limited has established itself as a key player in the pharmaceutical industry, with a strong focus on innovation and strategic partnerships. The company's diverse product offerings and recent financial performance highlight its potential for continued growth and profitability. With a solid market capitalization and a commitment to research and development, Daiichi Sankyo is well-positioned to capitalize on emerging opportunities in the healthcare sector.
AI Generated • Sep 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

20,171

CEO

Hiroyuki Okuzawa

Website

www.daiichisankyo.co.jp

Headquarters

Tokyo, TY 103-8426, JP

DSNKY Financials

Key Financial Metrics (TTM)

Gross Margin

68.47%

Operating Margin

8.83%

Net Income Margin

10.93%

Return on Equity

14.44%

Return on Capital

11.14%

Return on Assets

5.91%

Earnings Yield

5.08%

Dividend Yield

2.71%

Payout Ratio

59.07%

Stock Overview

Market Cap

$33.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.82B

Volume

76.71K

Avg. Volume

147.91K

Financials (TTM)

Gross Profit

¥1.55T

Operating Income

¥199.48B

EBITDA

¥315.94B

Operating Cash Flow

¥140.93B

Capital Expenditure

-¥138.41B

Free Cash Flow

¥2.52B

Cash & ST Invst.

¥633.64B

Total Debt

¥497.18B

Daiichi Sankyo, Performance Analysis

Daiichi Sankyo, annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 9,437,849,0681.5%
20242024-03-31JPY 11,090,991,16917.5%
20252025-03-31JPY 12,372,918,73811.6%
20262026-03-31JPY 14,088,629,81013.9%
Daiichi Sankyo, sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-307.4%
Q32025-12-3111.5%
Q42026-03-315.7%
Q12026-06-30-3.0%
Daiichi Sankyo, annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.4235.2%
20242024-03-31JPY 0.7272.5%
20252025-03-31JPY 1.0241.1%
20262026-03-31JPY 1.00-1.9%
Daiichi Sankyo, sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-45.9%
Q32025-12-3191.1%
Q42026-03-31-49.6%
Q12026-06-3061.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥582.31B

+22.7%

Gross Profit

¥456.38B

+19.4%

Gross Margin

78.37%

N/A

Market Cap

$33.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.64M

N/A

Employees

20,171

N/A

Net Income

¥69.54B

-18.7%

EBITDA

¥107.92B

-5.8%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥633.64B

+10.3%

Total Debt

¥497.18B

+147.1%

Accounts Receivable

¥672.45B

+9.9%

Inventory

¥728.21B

+29.1%

Long Term Debt

¥496.70B

+392.6%

Short Term Debt

¥474.84M

-99.5%

Return on Assets

5.91%

N/A

Return on Invested Capital

5.86%

N/A

Free Cash Flow

-¥17.13B

+73.8%

Operating Cash Flow

¥20.60B

+156.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLNCFHaleon plc
$4.32-4.51%
UCBJYUCB S.A.
$117.61-2.92%
UCBJFUCB S.A.
$246.64+0.21%
HOCPFHOYA Corporation
$144.80+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$77.36-0.23%
NVDANvidia
$227.21-0.72%
INTCIntel
$115.93-0.09%
SPCXSpace Exploration Technologies
$149.24+2.59%

Questions About DSNKY

What is the current price of Daiichi Sankyo,?

Daiichi Sankyo, is trading at $17.99 per share.

What is the 52-week range for Daiichi Sankyo,?

Over the past 52 weeks, Daiichi Sankyo, has traded between $14.98 and $27.50.

How much debt does Daiichi Sankyo, have?

As of the most recent reporting period, Daiichi Sankyo, reported total debt of ¥3.08B.

How much cash does Daiichi Sankyo, have on hand?

Daiichi Sankyo, reported ¥3.92B in cash and cash equivalents in its most recent financial results.

What is Daiichi Sankyo,’s dividend yield?

Daiichi Sankyo, currently has a dividend yield of 2.71%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services